glp-1 drug coverage What to Make of the and Cost Landscape GLP-1s and The Payer Predicament

32 It also significantly reduced the secondary composite HF endpoint (cardiovascular death, HF hospitalisation or urgent HF hospital visit), with an RRR of 18%

In the early stages of HF, compensatory mechanisms reduce the impact of the cardiac dysfunction

These effects are typically mild to moderate and often diminish over time with gradual dose titration

Marked insulinotropic effects have been observed in T2DM patients with a single injection of liraglutide (120) or acute infusion of exenatide (121)

However, these strategies often fall short of fully addressing the underlying metabolic challenges faced by transplant recipients

After at least 3 months of treatment, the pooled %TWL was 9.24% for liraglutide, 11.38% for semaglutide, and 15.50% for tirzepatide, with corresponding weight reductions of 8.56 kg, 11.62 kg, and 12.60 kg, respectively